Needham raised the price target for the I-Mab (NASDAQ:IMAB) stock to “a Buy”. The rating was released on March 15, 2021. We previously noted in another research note published on March 03, 2021 by H.C. Wainwright that reiterated the stock to a Buy with a price target of $75 for IMAB stock. The research report from Piper Sandler has initiated the stock to Overweight, with a price target set at $75. The stock was initiated by H.C. Wainwright, who disclosed in a research note on December 07, 2020, to Buy and set the price objective to $55. In their research brief published July 27, 2020, Cantor Fitzgerald analysts initiated the I-Mab stock to Overweight with a price target of $50.
Historical Earnings Surprises and Revenue Forecasts
It appears that the average earnings per share estimate for the current quarter (ending in Mar 2020) is $0. This is an average of 0 analysts’ earnings, where the high earnings per share estimate is $0 and the low earnings per share estimate is $0.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of I-Mab (NASDAQ:IMAB) raised 9.16% to close Thursday’s market session at $75.18, higher as compared to yesterday’s close. The stock price fluctuated between $69.00 and $77.80 throughout the trading session with the volume trading being 4597499 shares, which represented a significant variation when compared to the three months average volume of 467.77K shares. The firm’s stock price fluctuated 3.77% within the last five trades and 25.32% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 102.31% in the last 6 months and 27.01% was added to its value over the previous 3 months. IMAB stock is trading at a margin of 19.01%, 31.29% and 59.72% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, IMAB deals in the Healthcare domain. The stock is trading 2.08 percent below its 52-week high and 248.86 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 186.19. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does I-Mab’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $5.68 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for I-Mab (NASDAQ:IMAB) is 306.86. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 23.70 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 5.48, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.79 percent of I-Mab shares are owned by insiders, and 37.30 percent are held by financial institutions.